DSID,AU,TI,JR,PY,VL,IS,PG,AB,SA,REGID,STD.IND,STD.DESIGN,STD.GEO.LOCATION,STD.PHASE,ARM.NUM,ARM.BLIND,ARM.RANDFLG,ARM.TRT,ARM.TRTCLASS,ARM.DOSE,ARM.DOSEU,ARM.ROUTE,ARM.REGIMEN,ARM.FORMULATION,N.STUDY,N.ARM,N.ARM.STATANAL,N.ARM.EVENT.SUBJ,STATANAL.POP,STATANAL.METHOD,STATANAL.IMP.METHOD,ARM.TIME1,ARM.TIME1U,ENDPOINT,BSL.STAT,BSL.VAL,BSL.VALU,BSL.VAR,BSL.VARU,BSL.LCI,BSL.UCI,CHBSL.STAT,CHBSL.VAL,CHBSL.VALU,CHBSL.VAR,CHBSL.VARU,CHBSL.LCI,CHBSL.UCI,RSP.STAT,RSP.VAL,RSP.VALU,RSP.VAR,RSP.VARU,RSP.LCI,RSP.UCI,PCHBSL.STAT,PCHBSL.VAL,PCHBSL.VAR,PCHBSL.VARU,PCHBSL.LCI,PCHBSL.UCI,ARM.PCT.MALE,ARM.AGE,ARM.AGEU
544,Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ,"Dapagliflozins Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension",DIABETES.CARE,2015,38,7.0,1218~1227,,D1690C00018,NCT01031680,T2D;Cardiovascular disease;Obesity,Parallel,AR;CA;DE;RO;SK;ES;TW;US;VN,Phase 3,,Double-Blind,True,placebo,Placebo,0,MG/DAY,ORAL,QD,TAB,922,,234,,FAS,,LOCF,0.0,WK,HbA1c,Mean,8.16,percent,0.83,SD,,,LS Mean,0.0,percent,,,,,Mean,8.16,percent,0.83,SD,,,LS Mean,0.0,,,,,,,
544,Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ,"Dapagliflozins Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension",DIABETES.CARE,2015,38,7.0,1218~1227,,D1690C00018,NCT01031680,T2D;Cardiovascular disease;Obesity,Parallel,AR;CA;DE;RO;SK;ES;TW;US;VN,Phase 3,,Double-Blind,True,dapagliflozin,SGLT2,10,MG/DAY,ORAL,QD,TAB,922,,228,,FAS,,LOCF,0.0,WK,HbA1c,Mean,8.31,percent,0.85,SD,,,LS Mean,0.0,percent,,,,,Mean,8.31,percent,0.85,SD,,,LS Mean,0.0,,,,,,,
544,Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ,"Dapagliflozins Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension",DIABETES.CARE,2015,38,7.0,1218~1227,,D1690C00018,NCT01031680,T2D;Cardiovascular disease;Obesity,Parallel,AR;CA;DE;RO;SK;ES;TW;US;VN,Phase 3,,Double-Blind,True,placebo,Placebo,0,MG/DAY,ORAL,QD,TAB,922,,217,,FAS,,LOCF,0.0,WK,HbA1c,Mean,7.99,percent,0.76,SD,,,LS Mean,0.0,percent,,,,,Mean,7.99,percent,0.76,SD,,,LS Mean,0.0,,,,,,,
544,Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ,"Dapagliflozins Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension",DIABETES.CARE,2015,38,7.0,1218~1227,,D1690C00018,NCT01031680,T2D;Cardiovascular disease;Obesity,Parallel,AR;CA;DE;RO;SK;ES;TW;US;VN,Phase 3,,Double-Blind,True,dapagliflozin,SGLT2,10,MG/DAY,ORAL,QD,TAB,922,,220,,FAS,,LOCF,0.0,WK,HbA1c,Mean,8.05,percent,0.81,SD,,,LS Mean,0.0,percent,,,,,Mean,8.05,percent,0.81,SD,,,LS Mean,0.0,,,,,,,
544,Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ,"Dapagliflozins Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension",DIABETES.CARE,2015,38,7.0,1218~1227,,D1690C00018,NCT01031680,T2D;Cardiovascular disease;Obesity,Parallel,AR;CA;DE;RO;SK;ES;TW;US;VN,Phase 3,,Double-Blind,True,placebo,Placebo,0,MG/DAY,ORAL,QD,TAB,922,,234,,FAS,,LOCF,24.0,WK,HbA1c,Mean,8.16,percent,0.83,SD,,,LS Mean,0.19,percent,,95%CI,0.08,0.29,LS Mean,8.424,percent,,,,,LS Mean,2.307,,,,,,,
544,Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ,"Dapagliflozins Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension",DIABETES.CARE,2015,38,7.0,1218~1227,,D1690C00018,NCT01031680,T2D;Cardiovascular disease;Obesity,Parallel,AR;CA;DE;RO;SK;ES;TW;US;VN,Phase 3,,Double-Blind,True,dapagliflozin,SGLT2,10,MG/DAY,ORAL,QD,TAB,922,,228,,FAS,,LOCF,24.0,WK,HbA1c,Mean,8.31,percent,0.85,SD,,,LS Mean,-0.28,percent,,95%CI,-0.39,-0.17,LS Mean,7.954,percent,,,,,LS Mean,-3.401,,,,,,,
544,Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ,"Dapagliflozins Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension",DIABETES.CARE,2015,38,7.0,1218~1227,,D1690C00018,NCT01031680,T2D;Cardiovascular disease;Obesity,Parallel,AR;CA;DE;RO;SK;ES;TW;US;VN,Phase 3,,Double-Blind,True,placebo,Placebo,0,MG/DAY,ORAL,QD,TAB,922,,217,,FAS,,LOCF,24.0,WK,HbA1c,Mean,7.99,percent,0.76,SD,,,LS Mean,-0.02,percent,,95%CI,-0.13,0.1,LS Mean,8.0,percent,,,,,LS Mean,-0.249,,,,,,,
544,Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ,"Dapagliflozins Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension",DIABETES.CARE,2015,38,7.0,1218~1227,,D1690C00018,NCT01031680,T2D;Cardiovascular disease;Obesity,Parallel,AR;CA;DE;RO;SK;ES;TW;US;VN,Phase 3,,Double-Blind,True,dapagliflozin,SGLT2,10,MG/DAY,ORAL,QD,TAB,922,,220,,FAS,,LOCF,24.0,WK,HbA1c,Mean,8.05,percent,0.81,SD,,,LS Mean,-0.47,percent,,95%CI,-0.59,-0.36,LS Mean,7.55,percent,,,,,LS Mean,-5.86,,,,,,,
